{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:23:43Z","timestamp":1787765023562,"version":"build-2784847793"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>\n                    Hyperphosphatemia is an electrolyte disorder highly prevalent in patients with chronic kidney disease undergoing hemodialysis (HD) that usually requires treatment with oral phosphate binders (PBs). Sucroferric oxyhydroxide (SO) is a calcium-free, iron-based PB indicated for the control of serum phosphorus. In the real-world setting, SO has shown clinical effectiveness with a lower pill burden and has also been associated with reduced hospital admission rates. This study aims to assess the potential economic benefits resulting from the introduction of SO to the health-care setting of the Kingdom of Saudi Arabia (KSA). An economic analysis using data from a retrospective real-world study that compared HD patients with uninterrupted SO prescriptions with patients who discontinued SO and switched to other PBs (oPBs). Annual drug costs for the estimated PB-eligible population in KSA were quantified. Costs per responder were estimated for all treatments. Hospital admissions' incidence rates were converted into annual inpatient cost savings and were deducted from drug costs to estimate the annual economic effect of SO versus oPBs. Sensitivity and breakeven analyses were also conducted. The eligible population for PB therapy in KSA was estimated at\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 14,748. Treating therapy-eligible populations exclusively with SO was estimated to generate annual inpatient cost-savings of SAR 107.4\u2013119.4 million compared to treating the population with oPBs. The estimated economic effect signified overall annual savings ranging from SAR 82.8 to SAR 94.8 million when the population is treated with SO. Sensitivity analyses showed persistent cost savings. The estimated benefit\u2013cost ratios showed that for every SAR 1 spent on SO, the expected return on investment was SAR 4.4\u20134.9. SO is an effective therapy that may result in substantial cost savings from reducing hospital admission costs that are attributable to hyperphosphatemia among HD patients.\n                  <\/jats:p>","DOI":"10.4103\/1319-2442.391887","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T06:08:07Z","timestamp":1703311687000},"page":"100-110","source":"Crossref","is-referenced-by-count":0,"title":["Health Economic Benefits of Introducing Sucroferric Oxyhydroxide in the Treatment of Patients with Chronic Kidney Disease under Dialysis in the Kingdom of Saudi Arabia"],"prefix":"10.4103","volume":"34","author":[{"given":"Saeed M. G","family":"Al-Ghamdi","sequence":"first","affiliation":[{"name":"Department of Medicine, Nephrology Section, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"},{"name":"Department of Medicine, Nephrology Section, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Hashim","family":"Almalki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nephrology Section, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia"},{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Altowaijri","sequence":"additional","affiliation":[{"name":"Clinical Insights and Innovation Director, Center of National Health Insurance, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Al-Gabash","sequence":"additional","affiliation":[{"name":"CSL Vifor, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kotsopoulos","sequence":"additional","affiliation":[{"name":"Global Market Access Solutions, St-Prex, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"R1-20231226","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ki.2009.60","article-title":"Oral phosphate binders","volume":"75","author":"Hutchison","year":"2009","journal-title":"Kidney Int"},{"key":"R2-20231226","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14740338.2014.907791","article-title":"Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: A comparison of safety profiles","volume":"13","author":"Locatelli","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"R3-20231226","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R4-20231226","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R5-20231226","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca \u00d7 PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R6-20231226","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","article-title":"Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study","volume":"16","author":"Slinin","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R7-20231226","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1523-1755.2003.00064.x","article-title":"Nonadherence in hemodialysis: Associations with mortality, hospitalization, and practice patterns in the DOPPS","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"R8-20231226","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ekir.2019.06.002","article-title":"Strategies for phosphate control in patients with CKD","volume":"4","author":"Barreto","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R9-20231226","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40620-019-00689-w","article-title":"Phosphate binders in chronic kidney disease: An updated narrative review of recent data","volume":"33","author":"Floege","year":"2020","journal-title":"J Nephrol"},{"key":"R10-20231226","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int"},{"key":"R11-20231226","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R12-20231226","doi-asserted-by":"crossref","first-page":"c108","DOI":"10.1159\/000337087","article-title":"Non-calcium-containing phosphate binders: Comparing efficacy, safety, and other clinical effects","volume":"120","author":"Fraz\u00e3o","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"R13-20231226","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial Int"},{"key":"R14-20231226","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-20231226","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CN108119","article-title":"The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro","volume":"81","author":"Wilhelm","year":"2014","journal-title":"Clin Nephrol"},{"key":"R18-20231226","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"R19-20231226","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","article-title":"One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis","volume":"32","author":"Floege","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R20-20231226","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ekir.2020.12.029","article-title":"Prevalence and associated factors of chronic kidney disease among relatives of hemodialysis patients in Saudi Arabia","volume":"6","author":"Mousa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R21-20231226","first-page":"1012","article-title":"Dialysis in the kingdom of Saudi Arabia","volume":"29","year":"2018","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"R22-20231226","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.xkme.2020.01.009","article-title":"Sucroferric oxyhydroxide in maintenance hemodialysis: A retrospective, comparative cohort study","volume":"2","author":"Coyne","year":"2020","journal-title":"Kidney Med"},{"key":"R23-20231226","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/13696998.2021.1996957","article-title":"Estimating hospital inpatient cost-savings with sucroferric oxyhydroxide in patients on chronic hemodialysis in five European countries: A cost analysis","volume":"24","author":"Herrero","year":"2021","journal-title":"J Med Econ"},{"key":"R24-20231226","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4103\/1319-2442.185242","article-title":"Comparison of total direct cost of conventional single use and mechanical reuse of dialyzers in patients of end-stage renal disease on maintenance hemodialysis: A single center study","volume":"27","author":"Qureshi","year":"2016","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R25-20231226","first-page":"78","article-title":"The cost of hemodialysis in a large hemodialysis center","volume":"23","author":"Al Saran","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R26-20231226","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.sjbs.2020.10.055","article-title":"Development of unit cost for the health services offered at King FAHD Central hospital Jazan, Saudi Arabia","volume":"28","author":"Ghilan","year":"2021","journal-title":"Saudi J Biol Sci"},{"key":"R27-20231226","article-title":"SCOT Annual Report for Organ Transplantation in Kingdom of Saudi Arabia","year":"2019"},{"key":"R28-20231226","doi-asserted-by":"crossref","first-page":"e74996","DOI":"10.1371\/journal.pone.0074996","article-title":"Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: A large community based cohort study","volume":"8","author":"McGovern","year":"2013","journal-title":"PLoS One"},{"key":"R29-20231226","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","article-title":"Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS)","volume":"44","author":"Young","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R30-20231226","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The dialysis outcomes and practice patterns study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R31-20231226","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/ndt\/gfy093","article-title":"Serum phosphate optimal timing and range associated with patients survival in haemodialysis: The COSMOS study","volume":"34","author":"Fern\u00e1ndez-Mart\u00edn","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R32-20231226","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.ajkd.2020.05.025","article-title":"State-of- the-art management of hyperphosphatemia in patients with CKD: An NKF-KDOQI controversies perspective","volume":"77","author":"Scialla","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R33-20231226","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40265-017-0798-x","article-title":"Erratum to: A review of phosphate binders in chronic kidney disease: Incremental progress or just higher costs?","volume":"77","author":"St","year":"2017","journal-title":"Drugs"},{"key":"R34-20231226","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1681\/ASN.20203110S1163a","article-title":"An observational analysis of hospital admissions and total member costs associated with the use of various phosphate binders used in dialysis patients included in ESRD seamless care organizations","volume":"31","author":"Lindemann","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R36-20231226","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4103\/1319-2442.256858","article-title":"Etiology and frequency of hospital admissions in maintenance hemodialysis patients in chronic kidney disease","volume":"30","author":"Nath","year":"2019","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R37-20231226","first-page":"199","article-title":"Economic burden of hemodialysis","volume":"5","author":"Jali","year":"2016","journal-title":"Glob Adv Res J Med Med Sci"},{"key":"R38-20231226","first-page":"1279","article-title":"The burden of ischemic heart disease at a major cardiac center in Central Saudi Arabia","volume":"32","author":"Osman","year":"2011","journal-title":"Saudi Med J"},{"key":"R39-20231226","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3747\/pdi.2013.00305","article-title":"Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system","volume":"34","author":"Liu","year":"2014","journal-title":"Perit Dial Int"},{"key":"R40-20231226","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1111\/j.1523-1755.2005.09504.x","article-title":"The role of daily dialysis in the control of hyperphosphatemia","volume":"95","author":"Achinger","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"R41-20231226","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s40273-015-0320-9","article-title":"Cost effectiveness of sucroferric oxyhydroxide compared with sevelamer carbonate in the treatment of hyperphosphataemia in patients receiving dialysis, from the perspective of the national health service in Scotland","volume":"33","author":"Gutzwiller","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"R42-20231226","article-title":"(Scottish Medicines Consortium), S.M.C., Sucroferric Oxyhydroxide 500 mg Chewable Tablets (Velphoro\u00ae)","journal-title":"Medicines advice SMC ID: 1035\/15; 2015"}],"container-title":["Saudi Journal of Kidney Diseases and Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-2442.391887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:57:30Z","timestamp":1787763450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-2442.391887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/1319-2442.391887","relation":{},"ISSN":["1319-2442","2320-3838"],"issn-type":[{"value":"1319-2442","type":"print"},{"value":"2320-3838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}